Navigation Links
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Date:9/2/2008

p>About the Roche/InterMune Collaboration

In October 2006, Roche and InterMune announced an exclusive worldwide collaboration to develop and commercialize products from InterMune's HCV protease inhibitor program, including ITMN-191. The companies also collaborate on a research program to identify, develop and commercialize novel second-generation HCV protease inhibitors.

At closing, InterMune received from Roche an upfront payment of $60 million, and in 2007 received a $10 million manufacturing milestone and a $10 million development milestone. In addition to the $15 million milestone being announced today, assuming the continued successful development and commercialization of ITMN-191 in the United States and other countries, InterMune could potentially receive up to an additional $435 million in milestones.

Roche funds 67% of the global development costs of ITMN-191. The companies will co-commercialize the product in the United States and share profits on a 50/50 basis. InterMune will receive royalties outside the United States.

Roche has rights to other HCV protease inhibitor development candidates resulting from the research collaboration. The economic terms for ITMN-191 also apply to additional compounds that InterMune and Roche may develop and commercialize.

In early April 2008, InterMune reported top-line results in the four dose cohorts of treatment-naive patients in a Phase 1b multiple-ascending-dose (MAD) monotherapy trial of ITMN-191 in patients chronically infected with HCV genotype 1. ITMN-191 demonstrated significant and rapid viral kinetic activity and excellent safety and tolerability in all dosage regimens. Also in early April, InterMune announced that 13-week preclinical studies in rats and monkeys were successfully completed which were necessary before initiation of clinical studies in Phase 2 with longer treatment durations than those performed to date with ITMN-191.

In late May 2008, InterMune initiated
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , October 1, 2014 ... to software invited to engage around the theme, ,Commercial ...     Elsevier , ... products and services, will host a gathering of some ... issues and trends impacting healthcare today and in the ...
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
(Date:9/30/2014)... Sept. 30, 2014 Report Details ... highest potential revenues Do you want to find ... you revenue predictions for those biological drugs from ... you find financial data, R&D trends, opportunities and ... sales forecasts to 2024 at overall world market, ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... Madison, Wis. The nation's dysfunctional healthcare system may ... adoption of electronic health records, according to a featured speaker ... Jeff Grossman Dr. Jeff Grossman, president and CEO ... perspective on the role of IT in healthcare delivery. As ...
... web site in your industry is a noble goal, a far ... ,The best means of measuring your web site's popularity is by ... of other web sites linking to it. Each time another web ... of confidence in your site and the quality of its content. ...
... England - A British court has ruled in favor of ... Apple Corps, Ltd. , a company the Beatles established in the ... that Apple Computer, Inc. is entitled to use the ... by Apple Corps. The dispute, which centered on a 1991 agreement, ...
Cached Biology Technology:U.S. health system could undermine EHR progress 2U.S. health system could undermine EHR progress 3Link Popularity: The Internet's 'In' Crowd 2Link Popularity: The Internet's 'In' Crowd 3Apple Computer may use Apple logo on iTunes 2
(Date:9/30/2014)... National Institutes of Health (NIH) awarded Lawrence Livermore ... an electrode array system that will enable researchers ... unprecedented resolution and scale. , LLNL,s grant-funded project ... Obama,s BRAIN (Brain Research through Advancing Innovative ... revolutionize our understanding of the human mind and ...
(Date:9/30/2014)... drinking water may increase the risk of stillbirth ... led by a Boston University School of Public ... journal Environmental Health , compared 1,091 PCE-exposed ... in Cape Cod, Ma., where water was contaminated ... by the installation of vinyl-lined asbestos cement pipes. ...
(Date:9/30/2014)... FRANKFURT. Truffles, along ... world. Because they grow underground, people use trained dogs or ... is not only of interest to gourmets. A group of ... University Frankfurt have discovered that the smell of white truffles ... truffle fruiting bodies. , White truffles from the Piedmont region ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Contaminated water linked to pregnancy complications, BU study finds 2On the trail of the truffle flavor 2
... 30, 2013) La Jolla Institute for Allergy ... a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd. ... the signing of a new agreement that marks another ... in the world. The six-year agreement continues a ...
... presented at the Annual Meeting of the Society for the ... into all aspects of eating and drinking behavior, shows that ... at risk to develop obesity and type 2 diabetes. ... stress exposure and passive stress coping style might predispose offspring ...
... be presented at the Annual Meeting of the Society for ... research into all aspects of eating and drinking behavior, found ... changes appear to be independent of taste nerve activity. ... and it is generally believed that reduced consumption is related ...
Cached Biology News:La Jolla Institute continues longtime collaboration with Kyowa Hakko Kirin California 2La Jolla Institute continues longtime collaboration with Kyowa Hakko Kirin California 3Taste preference changes in different life stages of rats 2
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
X box-binding protein 1...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Biology Products: